



11/12
Patent Docket P1099C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
William R. Arathoon et al.
Serial No.: 09/373,403
Filed: 12 August 1999
For: A METHOD FOR MAKING
MULTISPECIFIC ANTIBODIES
HAVING HETEROMULTIMERIC AND
COMMON COMPONENTS

Group Art Unit: 1642

Examiner: M. Davis

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in
an envelope addressed to: Assistant Commissioner of Patents,
Washington, D.C. 20231 on

February 20, 2001

Pamela Gavette

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This is responsive to the Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures dated December 19, 2000. Transmitted herewith are the following documents:

1. Sequence Listing, in paper copy and a computer readable diskette.
2. Certificate Re: Sequence Listing Response Under 37 CFR §1.821(f) and (g)
3. Copy of Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures.
4. Preliminary Amendment

The Commissioner is hereby authorized to deduct the appropriate surcharge fee associated with this communication or credit any overpayment to Deposit Account No. 07-0630. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

By:
Deirdre L. Conley
Reg. No. 36,487
Telephone No. (650) 225-2066

Date: February 20, 2001



09157



Patent Docket P1099C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

William R. Arathoon et al.

Serial No.: 09/373,403

Filed: 12 August 1999

For: A METHOD FOR MAKING
MULTISPECIFIC ANTIBODIES
HAVING HETEROMULTIMERIC AND
COMMON COMPONENTS

Group Art Unit: 1642

Examiner: M. Davis

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

February 20, 2001

Pamela Gavette

CERTIFICATE RE: SEQUENCE LISTING

RESPONSE UNDER 37 CFR § 1.821(f) and (g)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

By:
Deirdre L. Conley, Ph.D.
Reg. No. 36,487
Telephone No. (650) 225-2066



09157

PATENT TRADEMARK OFFICE

O
JC76
FEB 26 2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7.

Other: _____

Applicant must provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.